Abstract:AIM: To evaluate the efficacy and safety of bicyclol for chronic hepatits B(CHB). METHODS: CHB patients were randomly divided into bicyclol group and bifendate group on the ratio of 2∶1. Each group of patients received bicyclol or bifendate 2 mg tid for 24 wk, then stopped treatment and followed up 12 wk. Investigating items included clinical symptoms, liver function tests, serum hepatitis B (HBV) markers and safety profile. Efficacy evaluation was based on Intent To Treat (ITT) principle. RESULTS: Bicyclol or bifendate were given to two hundred and sixty nine and one hundred and thirty eight patients, respectively. The demographic and baseline features were similar in both groups. After bicyclol therapy, both clinical symptoms and serum ALT, AST levels were improved markedly. The normalization rates of ALT and AST were 53.5 % and 48.7 % at wk 24, and kept sustained normal in 40.2 % and 48.7 % at 12 wk after stop of treatment. In bifendate group, the ALT and AST normalization rates were 61.6 % and 44.2 % at wk 24, and 45.7 % and 50.0 % at 12 wk after stop of the treatment, respectively. The improvement of serum ALT and AST showed no statistical difference between two groups ( P 0.05). Regarding the HBV markers, in bicyclol group the negativity of HBeAg, HBeAg/Anti HBe seroconversion and negativity of HBV DNA at wk 24 were 20.8 % 15.6 % and 39.0 %, respectively, and then 29.0 %, 20.8 % and 45.7 % and 12 wk after stop of treatment. Whereas in bifendate group, those parameters were 15.2 %, 9.4 % and 37.7 % at wk 24, and 21.0 %, 14.5 % and 38.4 % at 12 wk after stop of treatment. These results between bicyclol and bifendate groups showed no significant statistical difference. However, in patients whose baseline ALT levels were higher than 5 times of upper limit of normal (200 U·L -1 ), the HBeAg negative rates and seroconversion rates at 12 wk after stop of treatment were significant higher in bicyclol group than those in bifendate group, those were 48 % versus 22 %( P = 0.015) and 38 % versus 12 % ( P =0.01). The adverse reactions of bicyclol group were mild and uncommon, only skin rash and dizzeness were occurred in one patient each; and skin rashes occurred in two and loss of appetite and nausea occurred in one patient who received bifendate. CONCLUSION: Bicyclol is effective for the improvement of the clinical symptoms and serum ALT and AST. Bicyclol is superior to bifendate on the clearance of serum HBeAg and seroconversion. It is well tolerated and safety throughout the course of trial.

The Analysis of the Efficacy and Reliability Hepatic Lesion Induced by Chlorpromazine or Clozapine Treated with Bicyclol

[Treatment of Chronic Hepatitis C by Bicyclum, a Randomized Double-Blind Placebo Controlled Trial].

Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug‐induced liver injury: A multicenter, randomized, phase II trial

Bicyclol for the Treatment of Drug-Induced Liver Injury: a Propensity Score Matching Analysis Using a Nationwide Inpatient Database

[The Analyse of Effectiveness in HBeAg-positive Chronic Viral Hepatitis B Treated by Adefovir Dipivoxil Combined with Bicyclol].

Therapeutic potential of bicyclol in liver diseases: Lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine

A Randomized Double-Blind Controlled Trial of Bicyclol in Treatment of Chronic Hepatitis B

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Efficacy and safety of bicyclol for treating patients with antituberculosis drug-induced liver injury

Effectiveness and Safety of Bicyclol Combined with Thymosin in Treatment of Chronic Viral Hepatitis B

Bicyclol Alleviates Signs of BDL-Induced Cholestasis by Regulating Bile Acids and Autophagy-Mediated HMGB1/p62/Nrf2 Pathway

Toxicity of Novel Anti-Hepatitis Drug Bicyclol: a Preclinical Study.

The efficacy of bicycol in treatment of chronic hepatitis B

Bicyclol ameliorates advanced liver diseases in murine models via inhibiting the IL-6/STAT3 signaling pathway

Bicyclol attenuates high fat diet-induced non-alcoholic fatty liver disease/non-alcoholic steatohepatitis through modulating multiple pathways in mice

Bicyclol alleviates high-fat diet-induced hepatic ER stress- and autophagy-associated non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in mice

A Randomized, Multi-Central, Controlled Study of Patients with Hepatitis B E Antigen-Positive Chronic Hepatitis B Treated by Adefovir Dipivoxil or Adefovir Dipivoxil Plus Bicyclol

Bicyclol Attenuates Pro-Inflammatory Cytokine and Chemokine Productions in CpG-DNA-stimulated L02 Hepatocytes by Inhibiting P65-Nf-kappab and P38-Mapk Activation.

Bicyclol ameliorates nonalcoholic fatty liver disease in mice via inhibiting MAPKs and NF-κB signaling pathways

A sexual dimorphism influences bicyclol-induced hepatic heat shock factor 1 activation and hepatoprotection

Clinical Trail of Decoction of Tonifying Qi Activating Blood and Detoxifcation in the Treatment of Chronic Hepatitis B Patients with Alanine Aminotransferase Less than Two-time upper Limits of Normal Level